Marrow Transplantation from Unrelated HLA-A,B,DR-Matched Volunteer Donors

Pg, Beatty; Hansen, JA; Anasetti, Claudio; Sanders, Jean E.; Cd, Buckner; Storb, Rainer; Ed, Thomas

doi:10.1007/978-3-662-39946-0_220

Cited by 7 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In approximately 75% of patients developing GvHD the skin is involved (10). Pruritus is often the first symptom, which is followed by an erythematous, lichenoid papular rash and dyspigmentation.…”

Section: Graft‐versus‐host Diseasementioning

confidence: 99%

“…In patients with chronic GvHD the ability to mount an immune response is severely altered. Healthy BMT survivors have suppressor cells that suppress donor responses to host antigens but do not interfere with the immune response to organisms (10). Patients with chronic GvHD have non‐specific suppressor cells that alter immune recovery.…”

Section: Immune Reconstitutionmentioning

confidence: 99%

“…They will have normal reproduction ability and will develop secondary sex characteristics. Young women who have mature gonadal function at the time of transplant will experience transient gonadal failure, although ovarian function usually returns 3–42 months post‐HSCT (10). In girls with delayed puberty, the use of oral contraceptives as a source of estrogen has been successful.…”

mentioning

confidence: 99%

“…A small percentage of males who received chemotherapy alone experience a normal progression through puberty and have azoospermia on semen analysis, whilst others have normal sperm counts. Sanders et al report one man with a return of sperm production who fathered a normal child 2 yr post‐transplant (10). In boys with delayed puberty the use of testosterone has been successful in achieving puberty.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Long‐term follow‐up in hematopoieticstem‐cell transplant patients

Fisher

1999

Pediatric Transplantation

View full text Add to dashboard Cite

Hematopoietic stem-cell transplantation (HSCT) has increasingly become an accepted treatment for many childhood diseases and disorders. Potential HSCT recipients can be children with hematological malignancies or solid tumors, as well as congenital and acquired disorders. In the past decade, the use of HSCT in the treatment of pediatric disorders has grown exponentially while advances in supportive care have improved survival rate, contributing to a rapidly growing population of transplant survivors. Although numerous similarities can be found between pediatric and adult long-term HSCT survivors, this article provides a brief overview of the pediatric patients, emphasizing the aspects of surveillance and late effects. Understanding the long-term complications that can occur after HSCT is important in determining the appropriate evaluations and medical treatment for the patient involved. The goal of this article is to assist caregivers in providing optimal care for long-term survivors of HSCT. The initial section of this work comprises the three major causes of late effects in HSCT. It will then encompass a system review of the different potential complications that are seen with HSCT.

show abstract

Section: Graft‐versus‐host Diseasementioning

confidence: 99%

Section: Immune Reconstitutionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Long‐term follow‐up in hematopoieticstem‐cell transplant patients

Fisher

1999

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…While the latter objectives have been largely realized (rejection rates are generally less than 5% with non-T-cell-depleted allogeneic transplants), the former goal remains problematic. Despite maximally tolerated doses of chemoradiotherapy, relapse probabilities, especially for advanced hematologic malignancies, remain disappointingly high [4][5][6]. Highdose chemoradiotherapy is also associated with substantial transplant-related toxicities and a significant incidence of acute and chronic graft-versus-host disease (GVHD) [7].…”

Section: Introductionmentioning

confidence: 99%

Nonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism

Spitzer

2000

The Oncologist

View full text Add to dashboard Cite

Experimental and clinical experiences have demonstrated successsful donor engraftment following nonmyeloablative preparative regimens. These less toxic conditioning strategies may be better tolerated with diminished transplant-related morbidity and mortality. Importantly, the intentional induction of mixed chimerism can be established following nonmyeloablative conditioning. This approach has the potential advantages of inhibiting graft-versus-host disease, presumably secondary to the persistence of host immunoregulatory cells, and providing a platform for the delivery of adoptive cellular immunotherapy with donor leukocyte infusions for patients with an underlying malignancy. This review will describe the preclinical evolution of nonmyeloablative transplant strategies, the rationale for considering these approaches, and the preliminary clinical experience with this novel allogeneic stem cell therapy.

show abstract

Selection of marrow donors for patients lacking an HLA-identical sibling

Anasetti¹

1990

Cancer Treatment and Research

View full text Add to dashboard Cite

Marrow Transplantation from Unrelated HLA-A,B,DR-Matched Volunteer Donors

Cited by 7 publications

References 3 publications

Long‐term follow‐up in hematopoieticstem‐cell transplant patients

Long‐term follow‐up in hematopoieticstem‐cell transplant patients

Nonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism

Selection of marrow donors for patients lacking an HLA-identical sibling

Contact Info

Product

Resources

About